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associated with variation in body composition and fasting 
lipid traits in Yup’ik Eskimos.  J. Lipid Res. 2012.  53: 
175–184. 
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 Obesity is associated with a series of metabolic condi-
tions clinically referred to as metabolic syndrome, which 
includes hypertension, dyslipidemia, hyperglycemia, and 
the development of type 2 diabetes (T2D). Approximately 
sixty percent of obese individuals have metabolic compli-
cations ( 1 ); however, “healthy obese” individuals have 
been identifi ed with excessive accumulation of body fat 
that does not translate to dyslipidemia and insulin resis-
tance ( 2, 3 ). For example, some Eskimo/Inuit people in-
digenous to Alaska are obese, but they have historically 
demonstrated low prevalence of insulin resistance, meta-
bolic syndrome, and T2D ( 4–7 ). Specifi cally, Yup’ik 
Eskimo peoples living in Southwest Alaska have obesity 
prevalence comparable to the general US population, yet 
the prevalence of metabolic syndrome ( 8 ) and T2D ( 9 ) is 
signifi cantly less than that observed in the general US pop-
ulation ( 10, 11 ). Although the mechanisms that allow 
 Abstract  Variants of carnitine palmitoyltransferase 1A 
( CPT1A ), a key hepatic lipid oxidation enzyme, may infl u-
ence how fatty acid oxidation contributes to obesity and 
metabolic outcomes.  CPT1A is regulated by diet, suggesting 
interactions between gene variants and diet may infl uence 
outcomes. The objective of this study was to test the associa-
tion of  CPT1A variants with body composition and lipids, 
mediated by consumption of polyunsaturated fatty acids 
(PUFA). Obesity phenotypes and fasting lipids were mea-
sured in a cross-sectional sample of Yup’ik Eskimo individu-
als (n = 1141) from the Center of Alaska Native Health 
Research (CANHR) study. Twenty-eight tagging  CPT1A 
SNPs were evaluated with outcomes of interest in regression 
models accounting for family structure. Several  CPT1A 
polymorphisms were associated with HDL-cholesterol and 
obesity phenotypes. The P479L (rs80356779) variant was 
associated with all obesity-related traits and fasting HDL-
cholesterol. Interestingly, the association of P479L with 
HDL-cholesterol was still signifi cant after correcting for 
body mass index (BMI), percentage body fat (PBF), or waist 
circumference (WC).  Our fi ndings are consistent with the 
hypothesis that the L479 allele of the  CPT1A P479L variant 
confers a selective advantage that is both cardioprotective 
(through increased HDL-cholesterol) and associated with 
reduced adiposity. —Lemas, D. J., H. W. Wiener, D. M. 
O’Brien, S. Hopkins, K. L. Stanhope, P. J. Havel, D. B. Alli-
son, J. R. Fernandez, H. K. Tiwari, and B. B. Boyer.  Genetic 
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candidate gene for obesity ( 34 ) and  CPT1A SNPs are as-
sociated with elevated fasting HDL-cholesterol levels ( 35 ), 
it is unknown whether the interaction between n-3 PUFA 
intake and  CPT1A SNPs infl uence changes in body com-
position and fasting lipids. 
 In this study, we tested the hypothesis that SNPs within 
or near the  CPT1A gene are associated with body composi-
tion and fasting lipid phenotypes in a large cross-sectional 
cohort of Yup’ik Eskimo peoples, a population whose daily 
dietary intake involves a 30-fold range of exposure of n-3 
PUFA, and we examined whether these associations were 
modifi ed by n-3 PUFA intake. 
 METHODS 
 Subjects and study design 
 The Center for Alaska Native Health Research (CANHR) stud-
ies genetic, behavioral, and dietary risk factors underlying obesity 
and their relationship to diabetes and cardiovascular disease 
among Yup’ik Eskimo peoples ( 9 ). A community-based participa-
tory research framework guides all CANHR investigations; par-
ticipant ascertainment is open to all members of the community 
meeting a specifi ed age minimum. Recruitment of Yup’ik Eskimo 
participants was initiated in 2003 and continues in 11 Southwest 
Alaska communities. All residents 14 years of age and older are 
invited to participate, and the resulting distribution of age in our 
study sample refl ects the age distribution among eligible partici-
pants according to 2000 US census data. Participants sign in-
formed-consent documents before entering the study using 
protocols that were approved by the University of Alaska Institu-
tional Review Board, the National and Alaska Area Indian Health 
Service Institutional Review Boards, and the Yukon-Kuskokwim 
Health Corporation Human Studies Committee. The analyses in 
this report were performed on 1,141 nonpregnant Yup’ik Eskimo 
participants with ages that ranged between 14 and 94 years at the 
time of enrollment. 
 Anthropometric and biochemical measurements 
 Anthropometric measurements were obtained by trained staff 
using protocols from the NHANES III Anthropometric Proce-
dures Manual ( 36 ) as previously described ( 8 ). These measure-
ments included height, weight, and four circumferences (waist, 
hip, triceps, and thigh). Percentage body fat was measured by 
electrical bioimpedance using a Tanita TBF-300A body composi-
tion analyzer (Tanita Corp., Arlington Heights, IL). Blood sam-
ples were collected from participants after an overnight fast, and 
lipoprotein measures, including total cholesterol, HDL-choles-
terol, LDL-cholesterol, VLDL-cholesterol, apolipoprotein A-I, 
and plasma triglycerides levels, were assayed as previously de-
scribed by Boyer et al. ( 8 ). 
 Biomarker for marine n-3 PUFA intake: analysis of RBC 
nitrogen stable isotope ratio 
 n-3 PUFA intake was assessed in Yup’ik Eskimo individuals us-
ing the nitrogen stable isotope ratio (  15 N) of red blood cells 
(RBC) as previously described ( 37 ). RBC aliquots were auto-
claved for 20 min at 121°C to destroy blood-borne pathogens, 
and samples were weighed into 3.5 × 3.75 mm tin capsules and 
freeze dried to a fi nal mass of 0.2–0.4 mg. Samples were analyzed 
at the Alaska Stable Isotope Facility by continuous-fl ow isotope 
ratio mass spectrometry, using a Costech ECS4010 Elemental 
Analyzer (Costech Analytical Technologies, Valencia, CA) inter-
faced to a Finnigan Delta Plus XP isotope ratio mass spectrometer 
Yup’ik Eskimo people to carry excess body fat without 
developing features of metabolic syndrome and T2D 
are unknown, dietary and genetic factors are likely to be 
relevant ( 12, 13 ). Because weight loss as a treatment for 
obesity-related comorbidities is difficult to achieve and 
maintain ( 14–17 ), understanding the underlying mecha-
nisms that protect this population from features of 
meta bolic syndrome despite their adiposity would have 
implications for treatment of obesity without the necessity 
of weight loss. 
 It has been proposed that the “healthy obesity” observed 
in Yup’ik Eskimo individuals is in part related to exposure 
to a diet rich in n-3 polyunsaturated fatty acids (n-3 PUFA) 
( 18, 19 ). n-3 PUFAs consumed by Yup’ik Eskimo people 
are principally composed of eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA), and their PUFA intake 
is 20 times greater than the current mean intake of the 
general US population (4.1 ± 0.5 g/day versus 0.05 g/day 
in men; 2.8 ± 0.3 g/day versus 0.09 g/day in women) ( 20, 
21 ). Cross-sectional studies in a Yup’ik Eskimo population 
offer a unique opportunity to examine the association of 
elevated n-3 PUFA exposure with body composition, fast-
ing lipids, and lipoprotein levels. Studies in both animals 
and humans have demonstrated that EPA and DHA im-
pact body composition and circulating fasting lipid levels 
by modulating gene expression to favor increased fatty 
acid oxidation and reduction of fat deposition ( 22 ). Evi-
dence that elevated n-3 PUFA consumption has a direct 
infl uence on “healthy” obesity remains inconclusive ( 12, 
13 ) and warrants experimental designs that evaluate gene-
diet interactions that may mediate this effect in popula-
tions with elevated daily dietary intake of n-3 PUFA. 
 Mitochondrial carnitine palmitoyltransferase 1 ( CPT1 ), 
a member of the carnitine palmitoyltransferase family, is a 
gene that controls fatty acid oxidation in skeletal, adipose, 
and liver tissue ( 23 ). Fatty acid oxidation is often impaired 
in the obese condition ( 24, 25 ), which may contribute to 
hepatic steatosis, hepatic insulin resistance, and impaired 
hepatic lipid handling ( 26 ). CPT1 as a major control point 
for fatty acid oxidation may, therefore, be a key player in 
“healthy obesity,” especially if certain single nucleotide 
polymorphisms (SNP) are resistant to impaired fatty acid 
oxidation, which often accompanies obesity. Interestingly, 
as n-3 PUFA increases mitochondrial fatty acid oxidation 
by stimulating the activity of  CPT1 ( 27 ), the interaction 
between n-3 PUFAs and SNPs in CPT1 may improve 
lipid profi les. 
 Mammalian tissues express three  CPT1 isoforms:  CPT1A 
(liver),  CPT1B (muscle), and  CPT1C (brain), which are 
encoded on separate genes ( 28–30 ). In the presence of 
L-carnitine,  CPT1 facilitates the transfer of long-chain fatty 
acids (LCFA) across the mitochondrial membrane for 
  -oxidation ( 31 ). Mitochondrial   -oxidation of dietary 
and endogenous LCFA is tightly regulated through allos-
teric inhibition of  CPT1 by malonyl-CoA, an intermediate 
in fatty acid synthesis ( 32 ). In liver cells, the partnership 
between malonyl-CoA and CPT1A has been shown to be a 
key regulatory point that modulates the oxidation of di-
etary and endogenous LCFA ( 33 ). Although  CPT1A is a 
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(v1.07) ( 47 ) and determined allele frequencies for each SNP 
using the FREQ module in the program Statistical Analysis for 
Genetic Epidemiology (S.A.G.E., 2009). The present study re-
stricted analysis to only include SNPs with MAF   5% that did 
not deviate from HWE after Bonferroni correction ( P < 0.002). 
 Association analysis 
 Each SNP was tested for association with obesity-related phe-
notypes using the program ASSOC ( 48 ) in the Statistical Analysis 
for Genetic Epidemiology (S.A.G.E. 2009) software package, 
which can incorporate complex pedigree data, covariates, and 
interactions into association analysis. We included both demo-
graphic (age, community, and sex) and environmental covariates 
(  15 N) in the ASSOC analysis. Likelihood ratio statistics were cal-
culated to compare three nested models and test the null hypoth-
esis of no association between  CPT1A SNPs and obesity traits 
after including demographic and environmental covariates. Ef-
fect sizes (  ) are presented as the change in transformed pheno-
types according to minor allele that was determined in a linear 
model adjusted for demographic and environmental covariates. 
 Model 1 included baseline covariates (age, sex, community 
membership, and   15 N quartiles); Model 2 included baseline co-
variates and SNP to test for an additive genetic effect of SNP (de-
fi ned as the number of minor alleles); and Model 3 included 
baseline covariates, the additive genetic effect of SNP, and inter-
actions between the additive genetic effect and   15 N quartiles. 
Note that Model 3 is the only model to test directly gene-diet in-
teraction under the null hypothesis. We treated each phenotype 
tested as representing a separate family of null hypotheses and 
corrected for the number of tests within each family ( 49 ). Multi-
ple-test correction to control the familywise error rate was calcu-
lated according to the number of nonredundant SNPs with MAF 
  0.05 that were tested for association and interaction. Given the 
correlation among neighboring genetic markers, the effective 
number of nonredundant SNPs in this study was estimated using 
spectral decomposition of LD matrices ( 50, 51 ). 
 RESULTS 
 Characteristics of Yup’ik Eskimo participants 
 General clinical characteristics and descriptive statistics 
on Yup’ik Eskimo men and women are presented in  Table 
1 .  Yup’ik women in this study had a mean age of 37.6 (± 17.3) 
years, and men reported a mean age of 35.9 (±17.3) years. 
Women had signifi cantly greater body mass index (BMI), 
percentage body fat (PBF), hip circumference (HC), fast-
ing total cholesterol, HDL-cholesterol, and ApoA1 levels 
compared with men ( P < 0.05). According to the standard 
cutoff points for overweight (BMI = 25–29.9 kg/m 2 ) and 
obese (BMI   30 kg/m 2 ), 28.6% of women and 30.7% of 
men were overweight, whereas 37.0% of women and 7.9% 
of the men were classifi ed as obese. 
 Distribution of   15 N in study population 
 In 1,138 Yup’ik Eskimo participants, n-3 PUFA intake 
was assessed using RBC   15 N as a biomarker of EPA and 
DHA intake. Summary statistics grouped by gender and 
  15 N quartiles are reported in  Table 2 .  The mean   15 N 
value was 9.0‰ with a range of 6.2–15.2‰. This range 
was large relative to analytical precision (0.2‰) and was 
3.75 times greater than the RBC (clot)   15 N values previ-
ously reported for a random sample of US residents ( 52 ). 
via the Confl o III interface (Thermo-Finnigan Inc., Breman, Ger-
many). Isotope ratios were analyzed relative to IAEA-certifi ed ref-
erence materials calibrated to atmospheric nitrogen, for which 
 15 N/ 14 N = 0.0036765. By convention and for ease of interpretation, 
isotope ratios are presented as delta values in “permil” relative to 
atmospheric nitrogen:   15 N = [( 15 N/ 14 N sample –  
15 N/ 14 N standard )/
( 15 N/ 14 N standard )] · 1000‰. We concurrently prepared and ran 
multiple laboratory standards (peptone,   15 N = 7.00) to assess 
analytical accuracy and precision; these were analyzed after every 
eighth sample and gave values of   15 N = 7.01 ± 0.24‰ (mean ± SD). 
The range of isotopic variation in our dataset (9‰) was very 
large relative to analytical precision (0.2‰). We modeled the 
effects of n-3 PUFA intake as a categorical variable, and they were 
included in the association analysis. This categorical variable is 
hereafter referred to as   15 N. 
 SNP selection and genotyping 
 A comprehensive list of DNA variants were selected for geno-
typing within and near (5 kb upstream and 5 kb downstream) the 
 CPT1A gene collected from HapMap data, release 3, National 
Center for Biotechnology Information (NCBI) B36, dbSNP 126 
( 38 ). Given that no publically available genotypic information ex-
ists on Yup’ik Eskimo people, we referenced the Caucasian 
(CEU) and Han Chinese (CHB) populations in HapMap using 
the Seattle SNPs database (http://pga.mbt.washington.edu/) to 
identify potential genetic variants that may be common in our 
study population. A set of 27 maximally informative tagging SNPs 
(tSNP) were selected to represent common linkage disequilib-
rium clusters with the LDselect algorithm as implemented in the 
MultiPop-TagSelect program, using thresholds of r 2 = 0.80 and 
minor allele frequency (MAF) >1% ( 39, 40 ). We chose to relax 
our MAF criteria to include SNPs with MAF > 0.01 to genotype 
tagging SNPs in the  CPT1A gene that may be common (MAF   
0.05) in Yup’ik Eskimos despite being rare (MAF < 0.05) in CEU 
and CHB populations. We also included the nonsynonymous 
P479L (rs80356779)  CPT1A SNP for genotyping based on previ-
ous associations with elevated plasma HDL-cholesterol and apoli-
poprotein A-I levels in the Greenland Inuit ( 35 ). Genotyping of 
the 28 SNPs, including P479L, was carried out by allele-specifi c 
primer extension of multiplex amplifi ed products and detection 
using matrix-assisted laser desorption ionization time-of-fl ight 
spectrometry on a Sequenom iPLEX platform at the Broad Insti-
tute ( 41 ). Linkage disequilibrium (LD) among SNPs was based 
on pairwise haplotype frequencies calculated using the hapfreq 
command in the FBAT program ( 42 ). 
 Quality control of phenotypic and genotypic data 
 Simple linear models were fi t to each of the outcome variables 
using all of the covariates (age, sex, community membership) in-
cluded in the association models, and the distributions of the 
residuals were examined for normality with the R statistical pro-
gramming language (v2.10.1, R Development Core, 2009). Box-
Cox transformations were applied to traits whose residuals did 
not follow a normal distribution ( 43 ). Family data was extracted 
from a Progeny database (Progeny Software LLC, South Bend, 
IN) and merged into a single extended pedigree using PedMerge 
( 44 ). Genotypic data were tested for Mendelian inconsistencies 
using PEDCHECK ( 45 ). In this sample, Illumina IV linkage panel 
(Illumina, Inc., San Diego, CA) genotypes were available from an 
ongoing linkage study and were used to construct principal com-
ponents of ancestry (PCA) using the PCA program in the EIGEN-
STRAT analysis package ( 46 ). The second PCA discriminated the 
individuals in the study into two groups that correspond to the 
proximity of the community to the coast. On the basis of this ob-
servation, we defi ned a dichotomous community group variable. 
We assessed Hardy-Weinberg equilibrium (HWE) using PLINK 
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polymorphism with MAF   0.05 that deviated signifi cantly 
from Hardy-Weinberg proportions and was excluded from 
the analysis. The nonsynonymous P479L SNP was com-
mon in our sample, and the major L479 allele had a fre-
quency of 0.74. We selected the 11  CPT1A SNPs with MAF   
0.05 that did not deviate from HWE proportions for ge-
netic analysis ( Table 3 ). The spectral decomposition of LD 
matrix ( 50 ) estimated that 8 of the 11 markers with MAF   
0.05 were nonredundant genetic markers, and we cor-
rected our analysis for eight tests, setting the per-test   
level to <0.0063 (two-tailed). 
 Association between fasting lipid parameters and  CPT1A 
SNPs 
 The results of association analysis between fasting lipid 
traits and  CPT1A SNPs with MAF   0.05 are summarized 
in  Table 4 .  HDL-cholesterol was signifi cantly associated 
with seven SNPs: rs2278908 ( P = 0.0007,   =   2.3, SE = 0.7), 
rs3019598 ( P = 0.0014,   =   2.2, SE = 0.7), P479L 
( P = 0.0001,   =   1.0, SE = 0.3), rs11228372 ( P = 0.0013, 
  =   1.2, SE = 0.4), rs11228373 ( P < 0.0001,   =   1.3, SE = 
0.3), rs3019594 ( P < 0.0001,   =   1.4, SE = 0.3), and 
rs597316 ( P = 0.0014,   =   2.2, SE = 0.7). The rs11228373 
and rs3019594 SNPs were also signifi cantly associated with 
ApoA1 ( P = 0.0014,   =   1.1, SE = 0.4 and  P = 0.0008,   = 
  1.2, SE = 0.4, respectively) and total cholesterol ( P = 
0.0063,   =   0.7, SE = 0.2 and  P = 0.0031,   =   0.7, SE = 0.2, 
respectively) ( Table 4 ). Note that rs11228373 and 
rs3019594 are in moderately strong LD (r 2 = 0.75). The 
P479L variant was also associated with HDL-cholesterol 
( P = 0.0001) and was not in strong LD with either the 
rs11228373 (r 2 = 0.58) or rs3019594 (r 2 = 0.61) SNP (sup-
plementary Table I). Our model predicted that individu-
als homozygous for the common allele (L479) of P479L 
had elevated fasting HDL-cholesterol levels compared 
with individuals homozygous for the P479L minor allele 
(P479). After adjusting Model 2 for BMI, the  CPT1A SNPs 
(rs2278908 , rs3019598, P479L, rs11228373, rs3019594, 
and rs597316) associated with fasting total cholesterol, 
HDL-cholesterol, ApoA1 were still signifi cant (supplemen-
tary Table II). 
 Association between  CPT1A SNPs and obesity phenotypes 
 The results of association analysis between obesity traits 
and  CPT1A SNPs with MAF   0.05 are summarized in 
According to the linear relationship between RBC   15 N 
and RBC EPA reported elsewhere for this population ( 37 ), 
the corresponding mean EPA (% RBC fatty acids) was 
2.66% with a range of   0–9.1%. Measurement of   15 N by 
gender yielded means of 9.1‰ for females and 8.8‰ for 
males. The mean RBC   15 N values by quartile were 7.3‰, 
8.2‰, 9.1‰, and 11.0‰ in quartiles 1–4, respectively. 
These values correspond to EPA (% RBC fatty acids) 
quartile means of: 0.9%, 1.8%, 2.8%, and 4.7% ( 37 ). The 
standard deviation of   15 N in this sample did not differ by 
gender (1.5‰ for both females and males). 
 Genetic variation in the  CPT1A gene 
 DNA was available in 1,141 Yup’ik Eskimo participants, 
and the mean number of individuals successfully geno-
typed was 1,078 (range of 986–1,137, depending on the 
SNP). Twenty-eight  CPT1A SNPs were genotyped with a 
mean success rate of 94.7% (range 76.1–99.7%). In this 
sample, 4 SNPs were monomorphic, 12 SNPs had MAF < 
0.05 and MAF > 0.01, and 12 SNPs had MAF   0.05. Geno-
typing results for SNPs with MAF   0.05 are presented in 
 Table 3 .  The rs2924697 SNP (MAF = 0.28) was the only 
 TABLE 1. Descriptive statistics of obesity-related traits in 
Yup’ik Eskimos 
Women Men  P 
Variables
 No. of participants 601 539
 Age (yr) 37.6 ± 17.3 35.9 ± 17.4 0.1113
 Height (cm) 156.1 ± 6.2 167.7 ± 7.0 <0.0001
 Weight (kg) 69.8 ± 16.7 73.0 ± 15.6 0.0003
Obesity measures
 BMI (kg/m 2 ) 28.7 ± 6.8 25.9 ± 4.8 <0.001
 Percentage body fat (%) 35.1 ± 8.9 21.1 ± 8.0 <0.0001
 Waist circumference (cm) 90.4 ± 15.9 89.2 ± 14.0 0.2102
 Hip circumference (cm) 104.1 ± 12.8 96.7 ± 8.3 <0.0001
 Thigh circumference (cm) 51.1 ± 5.6 50.2 ± 5.4 0.0071
Lipid measures
 Cholesterol (mg/dl) 216.4 ± 44.6 208.9 ± 48.0 0.0088
 HDL (mg/dl) 64.8 ± 18.5 56.2 ± 15.4 <0.0001
 Apolipoprote
in A-I (mg/dl)
170.8 ± 26.7 159.5 ± 26.8 <0.0001
 LDL (mg/dl) 134.9 ± 36.5 135.9 ± 40.2 0.5500
 VLDL (mg/dl) 16.9 ± 8.8 17.3 ± 10.6 0.4760
 Triglyceride (mg/dl) 83.6 ± 42.8 84.8 ± 52.5 0.5967
Values are mean ± SD. Differences by gender are derived using 
Student t-test.
 TABLE 2. Distribution of the RBC nitrogen stable isotope ratio (  15 N), a concentration biomarker for long 
chain n-3 polyunsaturated fatty acid (n-3 PUFA) intake in Yup’ik Eskimos 
Sex Quartiles of   15 N a 
Total Women Men Q1 Q2 Q3 Q4
No. of participants 1138 598 540 272 278 290 298
Mean ± SD (‰) 9.0 ± 1.5 9.1 ± 1.5 8.8 ± 1.5 7.3 ± 0.3 8.2 ± 0.2 9.1 ± 0.3 11.0 ± 1.0
Maximum 15.2 15.2 13.5 7.8 8.6 9.8 15.2
Minimum 6.2 6.3 6.2 6.2 7.8 8.6 9.8
Range (‰) 9.0 8.9 7.3 1.6 0.81 1.2 5.4
Isotope ratios are presented as delta values in “permil” relative to atmospheric nitrogen:   15 N = [( 15 N/ 14 N sample – 
 15 N/ 14 N standard )/( 
15 N/ 14 N standard )] · 1000‰.
 a The relationship between   15 N and EPA follows the linear model: EPA (%RBC fatty acid) = 1.04 ·   15 N – 
6.7‰, as previously described for this population ( 37 ).
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obesity and fasting lipid phenotypes in this Yup’ik Eskimo 
study population and may infl uence the “healthy obesity” 
phenotype. Specifi cally, the P479L SNP was associated 
with all measures of body composition (BMI, PBF, HC, 
ThC, and WC) and fasting HDL-cholesterol levels. We 
found that individuals homozygous for the major L479 
allele of the P479L variant had reduced body fat and cen-
tral adiposity relative to individuals homozygous for the 
minor P479 allele. These data indicate that individuals car-
rying both copies of the L479 allele of the nonsynonomous 
P479L variant in  CPT1A have reduced adiposity and el-
evated HDL-cholesterol, even after controlling for BMI. 
Interestingly, when we investigated whether the P479L 
association with HDL was mediated by other obesity phe-
notypes, we found the L479 allele was still signifi cantly as-
sociated with HDL-cholesterol after correction for 
either PBF or WC (data not shown). We hypothesize that 
the L479 allele may contribute to “healthy obesity” ob-
served in Yup’ik Eskimo people by modulating hepatic 
lipid oxidation. 
 Three studies have previously investigated the infl uence 
of  CPT1A polymorphisms on obesity and lipid phenotypes 
in humans ( 35, 53, 54 ). Hirota and colleagues ( 54 ) found 
no association between  CPT1A polymorphisms and obesity 
or fasting lipid phenotypes in Japanese individuals with 
T2D. In a cross-sectional cohort of French-Canadians, 
Robitaille et al. reported an association between the non-
synonymous A275T (rs17610395) SNP with BMI ( P = 0.05) 
and waist circumference ( P = 0.008) only after accounting 
for dietary fat intake ( 53 ). Finally, in Greenland Inuit, 
Rajakumar et al. showed the L479 allele in the nonsyn-
onymous P479L variant was associated with elevated 
fasting HDL-cholesterol and ApoA1 levels ( 35 ). 
 The present study found an association between SNPs 
(rs2278908, rs3019598, and rs597316) investigated by Hirota 
et al. with fasting HDL-cholesterol and replicated the 
P479L association with fasting HDL-cholesterol and ApoA1 
levels reported by Rajakumar et al. We have shown that 
these SNPs were still signifi cantly associated with HDL-
cholesterol and ApoA1 after controlling for BMI, PBF, or 
WC. Furthermore, we used a log likelihood ratio test to 
determine whether the P479L SNP association with HDL-
cholesterol and ApoA1 was independent of the rs11228373 
and rs3019594 SNPs. We found that both rs11228373 and 
rs3019594 SNPs were still signifi cant predictors for HDL-
cholesterol and ApoA1 levels, even when P479L was al-
ready in the model. Given that the rs11228373 and 
rs3019594 SNPs were in moderately strong linkage dis-
equilibrium with P479L as measured by r 2 (r 2 = 0.58 and 
0.61, respectively), we cannot rule out the possibility that 
the apparent association with P479L is not due to a true 
association with either rs11228373 or rs3019594 or both. 
 We extend the fi ndings of Rajakumar et al. to show the 
L479 allele of P479L is also associated with reduced adi-
posity in an independent Eskimo/Inuit population. Inter-
estingly, our analysis did not replicate the A275T 
(rs17610395) association with BMI and WC reported by 
Robitaille et al. because this SNP was not included in the 
analysis due to a low MAF (MAF = 0.02). Factors that may 
 Table 5 .  Thigh circumference (ThC) was associated with 
seven SNPs: rs2278908 ( P = 0.0024,   = 2.1, SE = 0.7), 
rs2278907 ( P = 0.0002,   = 1.9, SE = 0.5), P479L ( P < 0.0001, 
  = 1.2, SE = 0.3), rs4930248 ( P = 0.0042,   = 1.3, SE = 0.5), 
rs11228372 ( P = 0.0011,   = 1.3, SE = 0.4), rs11228373 ( P = 
0.0006,   = 1.1, SE = 0.3), and rs3019594 ( P = 0.0001,   = 
1.3, SE = 0.3). Hip circumference was associated with fi ve 
SNPs: rs2278907 ( P = 0.0057,   = 1.2, SE = 0.4), P479L ( P < 
0.0001,   = 0.9, SE = 0.2), rs11228372 ( P = 0.0034,   = 0.9, 
SE = 0.3), rs11228373 ( P = 0.0063,   = 0.7, SE = 0.3), and 
rs3019594 ( P = 0.0005,   = 0.9, SE = 0.3). 
 The P479L SNP and rs3019594 (r 2 = 0.61 between these 
SNPs) were SNPs most signifi cantly associated with both 
thigh circumference and hip circumference ( P < 0.0001 
and  P = 0.0034, respectively). The P479L SNP was the only 
SNP associated with all obesity measures, which included 
BMI ( P = 0.0021,   = 0.7, SE = 0.2), percentage body fat 
( P = 0.0007,   = 0.0007, SE = 0.2), hip circumference ( P < 
0.0001,   = 0.9, SE = 0.2), thigh circumference ( P < 0.0001, 
  = 1.2, SE = 0.3), and waist circumference (WC;  P = 0.0006, 
  = 1.0, SE = 0.3). Individuals homozygous for the com-
mon P479L allele (L479) had a lower percentage body fat, 
smaller BMI, and reduced thigh, hip, and waist circumfer-
ences compared with P479 homozygotes ( Table 6 ). 
 DISCUSSION 
 CPT1A has been implicated as candidate obesity gene in 
a meta-analysis of whole-genome linkage studies ( 34 ); 
however, the contribution of  CPT1A polymorphisms to 
variation in the metabolic consequences of obesity and 
obesity phenotypes remains unclear. Our results demon-
strate that  CPT1A polymorphisms are associated with 
 TABLE 3. SNPs genotyped within and near the  CPT1A gene 
with MAF   0.05 
SNP a Allele b MAF c Genotype
Individuals 
Genotyped d HWE  P e 
AA AB BB
rs2278908 C/T 0.06 2 40 1024 1066 0.1004
rs2278907 A/G 0.09 9 54 1074 1137 0.0270
rs3019598 G/A 0.05 2 37 1011 1050 0.0664
P479L 
(rs80356779)
A/G f 0.26 44 272 759 1075 0.1080
rs2305508 C/T 0.47 158 507 407 1072 0.7469
rs4930248 T/C 0.10 10 88 974 1072 0.0369
rs3794020 C/T 0.34 103 447 461 1011 1
rs2924697 G/C 0.28 1 533 452 986 0
rs11228372 G/A 0.14 7 158 906 1071 1
rs11228373 G/C 0.20 27 192 913 1132 0.0077
rs3019594 C/T 0.21 26 185 861 1072 0.0120
rs597316 G/C 0.05 1 42 1026 1069 0.4096
AA, homozygous recessive for minor allele; AB, heterozygous; BB, 
homozygous dominant allele.
 a Seattle SNPs Genome Variation Server on March 2008 (dbSNP 
build 126) Version 5.01.
 b Major/ Minor allele.
 c MAF computed using FREQ module in S.A.G.E.
 d Number of individuals genotyped for each  CPT1A SNP.
 e Computed using PLINK.
 f The P479L SNP is an A → G missense mutation at nucleotide 
position c.1436 of  CPT1A , which results in the substitution of a 
conserved proline (P479) for a leucine (L479) at position 479 in the 
CPT1A polypeptide.
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association with body composition. Interestingly, inter-
actions between n-3 PUFA intake and rs3794020 and 
rs2305508 were associated with HDL-cholesterol and 
ApoA1 levels, whereby n-3 PUFA intake enhanced the pos-
itive association of rs3794020 and rs2305508 minor alleles 
on these traits. Although n-3 PUFA interactions with ge-
netic factors have received considerable attention, our re-
sults should be interpreted with caution given the sample 
size and nominal signifi cance. 
 We hypothesize that the observed association between 
the P479L variant on body composition and fasting lipid 
phenotypes in the presence of n-3 PUFA intake may, in 
part, explain the presence of a “healthy obese” phenotype 
among Yup’ik Eskimos. In humans, low rates of endoge-
nous lipid oxidation are associated with obesity ( 25 ), and 
mechanisms that alter an individual’s metabolic profi le in 
favor of fatty acid oxidation have been suggested to reduce 
account for differences in results reported in the present 
study may include, but are not limited to, differences in 
statistical analysis, small sample size, and population strati-
fi cation ( 55 ). Our study, however, benefi ted from a sample 
size large enough to detect signifi cant SNP associations, 
and we used a statistical approach that accounts for family 
structure while allowing for covariates. 
 Our Yup’ik Eskimo study population was ideally suited 
to investigate the contribution of n-3 PUFA and genetic 
factors to “healthy obesity” due to the 30-fold range of EPA 
and DHA consumption ( 20 ), which can be precisely esti-
mated in large samples using nitrogen stable isotope ratios 
from red blood cell samples ( 37 ). When we examined 
whether the interaction between n-3 PUFA intake and 
 CPT1A SNPs modifi es the association with “healthy obe-
sity” phenotypes (supplementary Table III), we did not 
fi nd signifi cant gene-diet interactions that modifi ed the 
 TABLE 5. Association of  CPT1A SNPs with obesity phenotypes 
Obesity Measures
SNP BMI PBF HC ThC WC
rs2278908 0.5137 0.4006 0.0179  0.0024 0.5103
(  = 0.4, SE = 0.6) (  = 0.4, SE = 0.5) (  = 1.4, SE = 0.6)  (  = 2.1, SE = 0.7) (  = 0.5, SE = 0.8)
rs2278907 0.3778 0.4339  0.0057  0.0002 0.6956
(  = 0.4, SE = 0.42) (  = 0.3, SE = 0.4)  (  = 1.2, SE = 0.4)  (  = 1.9, SE = 0.5) (  = 0.2, SE = 0.5)
rs3019598 0.7691 0.6930 0.0578 0.0089 0.9006
(  = 0.2, SE = 0.6) (  = 0.2,SE = 0.5) (  = 1.1, SE = 0.6) (  = 1.9, SE = 0.7) (  = 0.1, SE = 0.8)
P479L (rs80356779)  0.0021  0.0007  <0.0001  <0.0001  0.0006 
 (  = 0.7, SE = 0.2)  (  = 0.7, SE = 0.2)  (  = 0.9, SE = 0.2)  (  = 1.2, SE = 0.3)  (  = 1.0, SE = 0.3) 
rs2305508 0.7108 0.6326 0.7604 0.1701 0.4912
(  =   0.1, SE = 0.2) (  =   0.1, SE = 0.2) (  = 0.1, SE = 0.2) (  = 0.3, SE = 0.2) (  =   0.2, SE = 0.2)
rs4930248 0.2369 0.1874 0.0191  0.0042 0.1503
(  = 0.4, SE = 0.4) (  = 0.4, SE = 0.3) (  = 0.9, SE = 0.4)  (  = 1.3, SE = 0.5) (  = 0.7, SE = 0.5)
rs3794020 0.4386 0.2276 0.3897 0.8763 0.1390
(  =   0.2, SE = 0.2) (  =   0.2, SE = 0.2) (  =   0.2, SE = 0.2) (  = 0.0, SE = 0.2) (  =   0.4, SE = 0.3)
rs11228372 0.0277 0.0244  0.0034  0.0011 0.0294
(  = 0.7, SE = 0.3) (  = 0.6, SE = 0.3)  (  = 0.9, SE = 0.3)  (  = 1.3, SE = 0.4) (  = 0.9, SE = 0.4)
rs11228373 0.1605 0.2517  0.0063  0.0006 0.1095
(  = 0.4, SE = 0.3) (  = 0.3, SE = 0.2)  (  = 0.7, SE = 0.3)  (  = 1.1, SE = 0.3) (  = 0.5, SE = 0.3)
rs3019594 0.0294 0.0312  0.0005  <0.0001 0.0154
(  = 0.6, SE = 0.3) (  = 0.5, SE = 0.2)  (  = 0.9, SE = 0.3)  (  = 1.3, SE = 0.3) (  = 0.8, SE = 0.3)
rs597316 0.3342 0.6079 0.0731 0.0161 0.2518
(  = 0.6, SE = 0.6) (  = 0.3, SE = 0.5) (  = 1.1, SE = 0.6) (  = 1.8, SE = 0.7) (  = 0.9, SE = 0.8)
Association of  CPT1A SNPs in a linear regression model adjusted for age, sex, community membership, and n-3 PUFA intake. Estimates of effect 
size (  ) are reported using transformed phenotypes. Results are signifi cant at  P < 0.0063 (highlighted in bold). Multiple-test correction for eight 
tests for a phenotype was estimated using the spectral decomposition of LD matrix ( 50 ).
 TABLE 6. Obesity-related trait distribution within P479L (rs80356779) genotypes in Yup’ik Eskimos people 
Obesity Measures L479/L479 L479/P479 P479/P479  P 
 BMI (kg/m 2 ) 26.2 (24.4–28.1) 28.0 (25.3–31.3) 31.1 (26.2–37.8)  0.0021 
 Percentage body fat (%) 27.8 (24.9–30.7) 30.0 (25.8–34.3) 33.7 (26.8–41.0)  0.0007 
 Waist circumference (cm) 87.1 (82.7–91.9) 91.9 (85.2–99.8) 100.4 (88.1–116.4)  0.0006 
 Hip circumference (cm) 98.2 (95.1–101.7) 101.6 (96.8–107.3) 106.6 (98.0–118.2)  <0.0001 
 Thigh circumference (cm) 49.8 (48.0–51.7) 53.4 (50.6–56.4) 57.9 (52.9–63.5)  <0.0001 
Lipid Measures L479/L479 L479/P479 P479/P479  P 
 Cholesterol (mg/dl) 211.0 (197.4–225.6) 199.6 (181.6–219.8) 193.9 (166.5–266.8) 0.0834
 HDL (mg/dl) 58.3 (53.3–64.1) 53.3 (47.2–60.6) 49.6 (41.1–60.7)  0.0001 
 Apolipoprotein A-I (mg/dl) 164.2 (155.2–173.9) 156.1 (144.2–169.1) 150.1 (132.4–170.5)  0.0077 
 LDL (mg/dl) 134.6 (122.4–147.8) 128.1 (111.6–146.4) 125.0 (99.7–155.1) 0.6629
 VLDL (mg/dl) 15.1 (12.9–18.0) 15.8 (12.5–20.4) 17.2 (11.8–26.9) 0.6355
 Triglyceride (mg/dl) 71.7 (61.7–84.2) 75.4 (60.9–95.5) 83.0 (58.6–125.1) 0.1407
Values are reported as predicted mean (95% CI) obtained from ASSOC output. Association of the P479L 
(L479>P479) minor allele in the linear regression model adjusted for age, sex, community membership, and n-3 
PUFA intake. Results are signifi cant at  P < 0.0063 (highlighted in bold). Multiple-test correction for eight tests for 
a phenotype was estimated using the spectral decomposition of LD matrix ( 50 ).
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intake, in addition to further investigation of the  CPT1A 
gene in epidemiological studies among Arctic populations 
with variable n-3 PUFA intake, will be required to validate 
the larger public health impact of these results. This study 
lays the foundation for future population-specifi c dietary 
recommendations based on gene-diet interactions.  
 The authors thank the community fi eld research assistants who 
helped with the study recruitment and data collection. The 
CANHR team expresses sincere appreciation to all study 
participants and their communities for welcoming and teaching 
them so much about the Yup’ik way of life. 
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